Biomarkers In Seizure To Predict Recurrence and Severe Outcomes

Overview

We study the hypothesis that combination of Proteine S100 beta and Copeptin within normal ranges can rule out seizure recurrences and severe outcome, and allow early discharge from the emergency department

Prospective study for a 12 month period in Paris (France) and London (UK). Inclusion criteria : * seizure within 24h of attendance to an Emergency department (ED) * or seizure in the ED Exclusion Criterie : * pregnancy * prisoneer Primary endpoint : \- recurrence of seizure, hospitalisation more than 24 hours or death within seven days Secondary endpoint : * Hospital free days at day 7 and day 28 * Death, ICU admission, or neurosurgical intervention at day 7 and day 28 * Return visit to the ED or re admission at day 7 and day 28 data collection: * demographics * past medical history, medication * vital signs (Heart rate, temperature, Pulse oxymetry, blood pressure, GCS) on arrival * Pathology (White cell count, Sodium, Calcium, Glucose, lactate) * Protein S100B and Copeptin * Seizure characteristics (Witnessed, simple, partial, complex, provoked, acute symptomatic, idiopathic) * Discharge plan, outcomes Follow up at day 7 and day 28, hospital visit or phone call

Conditions

Eligibility

Locations (4)

Outcomes